ストックスクリーナーアプリを入手
2.12
0.95%
0.02
アフターアワーズ：
2.14
0.02
+0.94%
Black Diamond Therapeutics Inc (BDTX) 最新ニュース
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
BDTX Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 4.9% Share GainProfit Margin Analysis - vinanet.vn
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
BDTX Q2 2026 Earnings: Narrower-than-Expected Loss Signals Cost DisciplineROA Comparison - vinanet.vn
BDTX Q2 2026 Earnings: EPS Beat of 14.7% Overshadowed by 4.7% Share DeclineCapex Guidance - vinanet.vn
Black Diamond Therapeutics (BDTX) Dips 1.76% as Shares Test Key Support ZoneArms Index - vinanet.vn
Black (BDTX) Q2 2026 Results: EPS Comes in Above Forecast for the Current Session; Latest Reaction: Shares Finish 4.34% Lower in the Available RecordReturn On Assets - vinanet.vn
Black (BDTX) Move: Moves 4.16% Lower to $2.10 in Latest Trading; Levels: Traders Can Monitor the $1.99-$2.21 Range under the Current SnapshotVolume Rate Change - vinanet.vn
Black (BDTX) Results Versus Estimates: EPS Comes in Above Forecast for the Current Session; Share Response: The Share Price Adds 6.31% in Latest TradingProfit Growth Outlook - vinanet.vn
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Black Diamond Therapeutics Stock Price Forecast. Should You Buy BDTX? - StockInvest.us
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Maze Therapeutics, Inc. (MAZE) and Xtant Medical Holdings (XTNT) - The Globe and Mail
Black Diamond Settles HMI Cancer-Drug Discovery Patent Lawsuit - news.bloomberglaw.com
BDTX Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 5.56%Mid-Term Outlook - Vinanet
Weekly Recap: Silevertinib NSCLC Phase 2 efficacy and $110.5M cash runway - TradingView
Renaissance Technologies LLC Has $3.50 Million Stock Holdings in Black Diamond Therapeutics, Inc. $BDTX - MarketBeat
Black Diamond Therapeutics Inc (BDTX) Stock News Today - TradingKey
A Quick Look at Today's Ratings for Black Diamond Therapeutics(BDTX.US), With a Forecast Between $8 to $14 - Moomoo
Black Diamond Therapeutics Inc (BDTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q1 Earnings Forecast for BDTX Issued By HC Wainwright - MarketBeat
A Quick Look at Today's Ratings for Black Diamond Therapeutics(BDTX.US), With a Forecast Between $8 to $11 - Moomoo
Raymond James Reaffirms Outperform on BDTX Amid Promising NSCLC Trial Data - GuruFocus
Jefferies Optimistic on BDTX Ahead of Q4 Catalysts; Shares Trade Near 1-Year Low - GuruFocus
Piper Sandler Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
TD Cowen Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating - Moomoo
Black Diamond Therapeutics (NASDAQ:BDTX) Posts Earnings Results - MarketBeat
Black Diamond Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Black Diamond Therapeutics reports Q2 2026: $110.5M cash, $9.9M net loss - TradingView
Black Diamond Therapeutics, Inc. 2Q 2026: Revenue $0 Net income ($9.91M), EPS ($0.17) — 10-Q Summary - TradingView
Black Diamond Therapeutics Q2 net loss narrows year over year - TradingView
BDTX: Silevertinib demonstrated robust Phase 2 efficacy in NSCLC, supporting pivotal development plans - TradingView
Black Diamond Therapeutics (NASDAQ: BDTX) details Q2 loss and 2028 cash runway - Stock Titan
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
Black Diamond Therapeutics Q2 net loss narrows to $9.91 million; revenue remains no revenue - Bitget
BDTX Q2'26 Earnings: EPS estimate is (0.20) USD - TradingView
Black Diamond Therapeutics Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Black Diamond Therapeutics Inc (BDTX) Institutional Confidence - TradingKey
BDTX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
BDTX|Black Diamond Therapeutics Inc|Price:1.730|Chg%:-0.030 - TradingKey
Black Diamond Therapeutics (BDTX): BlackRock discloses 3.84M-share, 6.7% ownership - Stock Titan
Black Diamond Therapeutics Inc (BDTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Black Diamond Therapeutics Inc (BDTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Black Diamond Therapeutics, Inc. Revenue Breakdown – NASDAQ:BDTX - TradingView
Black Diamond Therapeutics Inc (BDTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BDTX|Black Diamond Therapeutics Inc|Price:1.760|Chg%:-0.080 - TradingKey
BDTX|Black Diamond Therapeutics Inc|Price:1.770|Chg%:+0.040 - TradingKey
Black Diamond Therapeutics Inc (BDTX) Balance Sheet - TradingKey
Black Diamond Therapeutics Inc (BDTX) Earnings Date & Reports & Earnings News - TradingKey
Black Diamond Therapeutics Inc (BDTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Black Diamond Therapeutics Inc (BDTX) Cash Flow - TradingKey
TradingKey - TradingKey
Black Diamond Therapeutics Inc (BDTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Black Diamond Therapeutics (NASDAQ:BDTX) Trading Down 1.1%Here's What Happened - MarketBeat
BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price & Overview - ChartMill
BDTX Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesAnalyst Earnings Estimate - vinanet.vn
Black Diamond Therapeutics (BDTX) 24th Annual Needham Virtual Healthcare Conference summary - Quartr
Black Diamond Therapeutics (BDTX) Edges Higher Amid Key Support TestSeasonality Effect - dars.gov.et
BDTX Q1 2026 Earnings: Narrowed Loss Beats Estimates as Development Progress ContinuesConsensus Beat Rate - dars.gov.et
T. Rowe Price (BDTX) lists 4.03M shares, 7.0% stake in amendment - Stock Titan
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside (NASDAQ:BDTX) - Seeking Alpha
BDTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Companies Like Black Diamond Therapeutics (NASDAQ:BDTX) Are In A Position To Invest In Growth - simplywall.st
BDTX SEC FilingsBlack Diamond Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Behbahani Ali - Moomoo
Black Diamond Therapeutics touts Silevertinib lung cancer data, eyes FDA path - MSN
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Raman Prakash - Moomoo
Black Diamond Therapeutics 2026 Annual Stockholder Meeting Results and Voting Outcomes - Minichart
Form 4 Black Diamond Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):